dc.contributor.author |
Richardson, Simone I.
|
|
dc.contributor.author |
Manamela, Nelia P.
|
|
dc.contributor.author |
Motsoeneng, Boitumelo M.
|
|
dc.contributor.author |
Kaldine, Haajira
|
|
dc.contributor.author |
Ayres, Frances
|
|
dc.contributor.author |
Makhado, Zanele
|
|
dc.contributor.author |
Mennen, Mathilda
|
|
dc.contributor.author |
Skelem, Sango
|
|
dc.contributor.author |
Williams, Noleen
|
|
dc.contributor.author |
Sullivan, Nancy J.
|
|
dc.contributor.author |
Misasi, John
|
|
dc.contributor.author |
Gray, Glenda G.
|
|
dc.contributor.author |
Bekker, Linda‑Gail
|
|
dc.contributor.author |
Ueckermann, Veronica
|
|
dc.contributor.author |
Rossouw, Theresa M.
|
|
dc.contributor.author |
Boswell, M.T.
|
|
dc.contributor.author |
Ntusi, Ntobeko A.B.
|
|
dc.contributor.author |
Burgers, Wendy A.
|
|
dc.contributor.author |
Moore, Penny L.
|
|
dc.date.accessioned |
2023-05-12T12:08:55Z |
|
dc.date.available |
2023-05-12T12:08:55Z |
|
dc.date.issued |
2022-02-15 |
|
dc.description.abstract |
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOCs) exhibit escape
from neutralizing antibodies, causing concern about vaccine effectiveness. However, while non-neutralizing
cytotoxic functions of antibodies are associated with improved disease outcome and vaccine protection, Fc
effector function escape from VOCs is poorly defined. Furthermore, whether VOCs trigger Fc functions with
altered specificity, as has been reported for neutralization, is unknown. Here, we demonstrate that the Beta
VOC partially evades Fc effector activity in individuals infected with the original (D614G) variant. However, not
all functions are equivalently affected, suggesting differential targeting by antibodies mediating distinct Fc
functions. Furthermore, Beta and Delta infection trigger responses with significantly improved Fc cross-reactivity
against global VOCs compared with D614G-infected or Ad26.COV2.S-vaccinated individuals. This suggests
that, as for neutralization, the infecting spike sequence affects Fc effector function. These data have
important implications for vaccine strategies that incorporate VOCs, suggesting these may induce broader
Fc effector responses. |
en_US |
dc.description.department |
Immunology |
en_US |
dc.description.department |
Internal Medicine |
en_US |
dc.description.librarian |
am2023 |
en_US |
dc.description.sponsorship |
The EDCTP2 program of the European Union’s Horizon 2020 program, Wellcome Centre for Infectious Diseases Research in Africa, the SA-MRC, MRC UK, NRF, the Lily and Ernst Hausmann Trust, the South African Research Chairs Initiative of the Department of Science and Innovation and National Research Foundation of South Africa, the SA Medical Research Council SHIP program, the Center for the AIDS Program of Research (CAPRISA) and an L’Oreal/UNESCO Women in Science South Africa Young Talents award. |
en_US |
dc.description.uri |
http://www.cell.com/cell-host-microbe/home |
en_US |
dc.identifier.citation |
Richardson, S.I, Manamela, N.P., Motsoeneng, B.M. et al. 2022, 'SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity', Cell Reports Medicine, vol. 3, art. 100510, pp. 1-8, doi : 10.1016/j.xcrm.2022.100510. |
en_US |
dc.identifier.issn |
1931-3128 (print) |
|
dc.identifier.issn |
1934-6069 (online) |
|
dc.identifier.other |
10.1016/j.xcrm.2022.100510 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/90658 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Cell Press |
en_US |
dc.rights |
© 2022 Authors.
This is an open access article under the CC BY-NC-ND IGO license. |
en_US |
dc.subject |
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) |
en_US |
dc.subject |
Vaccine |
en_US |
dc.subject |
Antibodies |
en_US |
dc.subject |
Infection |
en_US |
dc.subject |
Variants of concern (VOCs) |
en_US |
dc.title |
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity |
en_US |
dc.type |
Article |
en_US |